-
公开(公告)号:US20070059354A1
公开(公告)日:2007-03-15
申请号:US11460712
申请日:2006-07-28
CPC分类号: A61K9/2054 , A61K9/2018 , A61K9/2027 , A61K31/55
摘要: This invention relates to a once a day sustained release dosage form suitable for oral administration of oxcarbazepine. The once a day sustained release dosage form of oxcarbazepine includes oxcarbazepine and hydroxypropyl methylcellulose (HPMC) having a viscosity of 11,000 to 25,000 cps.
摘要翻译: 本发明涉及适合口服奥卡西平的一日一次缓释剂型。 奥卡西平的一日一次缓释剂型包括粘度为11,000至25,000cps的奥卡西平和羟丙基甲基纤维素(HPMC)。
-
公开(公告)号:US20060147530A1
公开(公告)日:2006-07-06
申请号:US10532296
申请日:2003-10-22
IPC分类号: A61K9/26
CPC分类号: A61K9/2027 , A61K9/2054 , A61K9/2077 , A61K9/2866 , A61K31/195 , A61K31/517
摘要: The present invention relates to pharmaceutical compositions of alfuzosin or pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof, that release the active ingredient over an extended period of time. The pharmaceutical composition can be a sustained release oral dosage form that includes a single functional layer and, optionally, one or more nonfunctional layers adjacent to the single functional layer. The single functional layer includes alfuzosin or pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof and one or more release retarding ingredients.
摘要翻译: 本发明涉及在长时间内释放活性成分的阿夫唑嗪或其药学上可接受的盐,溶剂合物,对映异构体或其混合物的药物组合物。 药物组合物可以是持续释放口服剂型,其包括单个功能层和任选的一个或多个与单个功能层相邻的非功能层。 单功能层包括阿夫唑嗪或其药学上可接受的盐,溶剂合物,对映异构体或其混合物和一种或多种释放阻滞成分。
-